Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized vs Intravenous Hypertonic Saline in ARDS
NCT06226402Recruiting
- Sponsor
- Tanta University
- Start
- Sep 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Randomised, open-label trial of hypertonic saline in acute respiratory distress syndrome (ARDS) (3 arms), sponsored by Tanta University. Primary endpoint: Number of patients who will need mechanical ventilation at 28 days. Started Sep 2023; status: recruiting.
02
Drugs
hypertonic saline
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT06226402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06226402.